Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Debt: 2022-2024

Historic Total Debt for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $189.0 million.

  • Axsome Therapeutics' Total Debt fell 0.26% to $187.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.6 million, marking a year-over-year decrease of 0.26%. This contributed to the annual value of $189.0 million for FY2024, which is 2.45% up from last year.
  • Axsome Therapeutics' Total Debt amounted to $189.0 million in FY2024, which was up 2.45% from $184.5 million recorded in FY2023.
  • Axsome Therapeutics' 5-year Total Debt high stood at $189.0 million for FY2024, and its period low was $100.2 million during FY2022.
  • Moreover, its 3-year median value for Total Debt was $184.5 million (2023), whereas its average is $157.9 million.
  • Data for Axsome Therapeutics' Total Debt shows a peak YoY skyrocketed of 84.18% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Total Debt (Yearly) stood at $100.2 million in 2022, then soared by 84.18% to $184.5 million in 2023, then climbed by 2.45% to $189.0 million in 2024.